On October 14, 2015, prosecutors from the U.S. Attorney’s Offices for the District of Massachusetts and the Southern District of New York subpoenaed Valeant Pharmaceuticals for details on its patient assistance programs, drug pricing, and distribution practices.
Valeant shares fell following this announcement, closing down 4.7 percent at $168.87. The shares stumbled further by 1.2 percent a week later after the company said that it formed a committee to review allegations against the company.
The company is under attack for sharply raising the prices of its drugs, a practice illegal in most developed countries but legal in the U.S. The company defended its practice by mentioning that it hired a consultant to review this aspect of the business. The consultant found “considerable room to increase the price of both drugs.”